Drug resistance to targeted therapies: Deja vu all over again

被引：154

作者：

Groenendijk, Floris H. ^{[1
]}

Bernards, Rene ^{[1
]}

机构：

[1] Netherlands Canc Inst, Canc Genom Ctr Netherlands, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands

来源：

MOLECULAR ONCOLOGY | 2014年 / 8卷 / 06期

基金：

欧洲研究理事会;

关键词：

Anticancer therapy; Drug resistance; Targeted therapy; Pathway reactivation; Endocrine therapy; Drug combinations; ESTROGEN-RECEPTOR-ALPHA; METASTATIC BREAST-CANCER; TO-MESENCHYMAL TRANSITION; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; GENE AMPLIFICATION; ENDOCRINE-THERAPY; TAMOXIFEN RESISTANCE; RAF INHIBITION; MEK INHIBITION;

D O I：

10.1016/j.molonc.2014.05.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A major limitation of targeted anticancer therapies is intrinsic or acquired resistance. This review emphasizes similarities in the mechanisms of resistance to endocrine therapies in breast cancer and those seen with the new generation of targeted cancer therapeutics. Resistance to single-agent cancer therapeutics is frequently the result of reactivation of the signaling pathway, indicating that a major limitation of targeted agents lies in their inability to fully block the cancer-relevant signaling pathway. The development of mechanism-based combinations of targeted therapies together with non-invasive molecular disease monitoring is a logical way forward to delay and ultimately overcome drug resistance development. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

引用

页码：1067 / 1083

页数：17

共 129 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] ESR1 amplification in breast cancer: controversy resolved? [J].

Albertson, Donna G. .

JOURNAL OF PATHOLOGY, 2012, 227 (01) :1-3

[3] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[4]

[Anonymous], YOGI BOOK I REALLY D

[5] HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study [J].

Arpino, G ;

Green, SJ ;

Allred, DC ;

Lew, D ;

Martino, S ;

Osborne, CK ;

Elledge, RM .

CLINICAL CANCER RESEARCH, 2004, 10 (17) :5670-5676

[6]

Awad MM, 2013, NEW ENGL J MED, V369, P1173, DOI [10.1056/NEJMc1309091, 10.1056/NEJMoa1215530]

[7] Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].

Bachelot, Thomas ;

Bourgier, Celine ;

Cropet, Claire ;

Ray-Coquard, Isabelle ;

Ferrero, Jean-Marc ;

Freyer, Gilles ;

Abadie-Lacourtoisie, Sophie ;

Eymard, Jean-Christophe ;

Debled, Marc ;

Spaeth, Dominique ;

Legouffe, Eric ;

Allouache, Djelila ;

El Kouri, Claude ;

Pujade-Lauraine, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724

[8] Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer [J].

Bardelli, Alberto ;

Corso, Simona ;

Bertotti, Andrea ;

Hobor, Sebastijan ;

Valtorta, Emanuele ;

Siravegna, Giulia ;

Sartore-Bianchi, Andrea ;

Scala, Elisa ;

Cassingena, Andrea ;

Zecchin, Davide ;

Apicella, Maria ;

Migliardi, Giorgia ;

Galimi, Francesco ;

Lauricella, Calogero ;

Zanon, Carlo ;

Perera, Timothy ;

Veronese, Silvio ;

Corti, Giorgio ;

Amatu, Alessio ;

Gambacorta, Marcello ;

Diaz, Luis A., Jr. ;

Sausen, Mark ;

Velculescu, Victor E. ;

Comoglio, Paolo ;

Trusolino, Livio ;

Di Nicolantonio, Federica ;

Giordano, Silvia ;

Siena, Salvatore .

CANCER DISCOVERY, 2013, 3 (06) :658-673

[9] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

[10] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

← 1 2 3 4 5 6 7 8 9 10 →